Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Diseases of the esophagus

• Publication date

  2016-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dote.12299PMID 25604309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Berberine radiosensitizes human nasopharyngeal carcinoma by suppressing hypoxia-inducible factor-1α expression

  2014cited by this paper
• Smac mimetic compound LCL161 sensitizes esophageal carcinoma cells to radiotherapy by inhibiting the expression of inhibitor of apoptosis protein

  2014cited by this paper
• Berberine enhances radiosensitivity of esophageal squamous cancer by targeting HIF-1α in vitro and in vivo

  2013cited by this paper
• PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy

  2013cited by this paper
• The role of PARP1 in the DNA damage response and its application in tumor therapy

  2012cited by this paper
• Advances in using PARP inhibitors to treat cancer

  2012cited by this paper
• Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft

  2011cited by this paper
• Cancer esearch apeutics , Targets , and Chemical Biology textual Synthetic Lethality of Cancer Cell Kill Based R he Tumor Microenvironment

  2010cited by this paper
• Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

  2010cited by this paper
• In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016

  2009cited by this paper
• Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance.

  2008cited by this paper
• Poly(ADP-Ribose) Polymerase 1 Promotes Tumor Cell Survival by Coactivating Hypoxia-Inducible Factor-1–Dependent Gene Expression

  2008cited by this paper
• 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

  2008cited by this paper
• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

  2008cited by this paper
• Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential.

  2008cited by this paper
• A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia.

  2008cited by this paper
• Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy

  2007cited by this paper
• Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models

  2007cited by this paper
• Poly(ADP-ribose): novel functions for an old molecule

  2006cited by this paper
• In Vitro and In Vivo: The Story of Nonoxynol 9

  2005cited by this paper
• Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells.

  2005cited by this paper
• Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase.

  2004cited by this paper
• INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.

  2002cited by this paper
• PARP is important for genomic stability but dispensable in apoptosis.

  1997cited by this paper
• The Basic Science of Oncology

  1989cited by this paper

• Update on Combination Strategies of PARP Inhibitors

  2024cites this paper
• The radiosensitivity of niraparib tosylate to esophageal squamous cell carcinoma is stronger under hypoxia and higher-pressure conditions

  2024cites this paper
• Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization

  2023cites this paper
• PARP inhibitors combined with radiotherapy: are we ready?

  2023cites this paper
• DNA as the main target in radiotherapy—a historical overview from first isolation to anti-tumour immune response

  2023cites this paper
• Radiotherapy-PARP inhibitor combinations: progress to date

  2022cites this paper
• Prognostic Implications of Six Altered Genes in Asian Non-Surgical Esophageal Carcinoma Patients Treated with Chemoradiotherapy

  2022cites this paper
• Prognostic Implications of Six Altered Genes in Asian Non-Surgical Esophageal Carcinoma Patients Treated with Chemoradiotherapy

  2022cites this paper
• Radiotherapy-Poly(ADP-ribose) Polymerase Inhibitor Combinations: Progress to Date.

  2022cites this paper
• Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers

  2021influential citation
• Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells

  2020cites this paper
• Olaparib Potentiates Anticancer Drug Cytotoxicity via 53BP1 in Oesophageal Squamous Cell Carcinoma Cells

  2020cites this paper
• Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models

  2020cites this paper
• BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies.

  2020influential citation
• A Comprehensive Analysis of Alterations in DNA Damage Repair Pathways Reveals a Potential Way to Enhance the Radio-Sensitivity of Esophageal Squamous Cell Cancer

  2020cites this paper
• Single-cell intratumoral stemness analysis reveals the involvement of cell cycle and DNA damage repair in two different types of esophageal cancer

  2019cites this paper
• Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia

  2019cites this paper
• mRNA and methylation profiling of radioresistant esophageal cancer cells: the involvement of Sall2 in acquired aggressive phenotypes

  2017cites this paper
• Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.

  2017cites this paper
• Contribut ion Hypoxia Potent iates the Radiat ion-Sensit izing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthet ic

  2016cites this paper
• An integrative framework to identify cell death-related microRNAs in esophageal squamous cell carcinoma

  2016cites this paper
• Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality

  2016cites this paper
• In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio.

  2015cites this paper